Why Journey Medical Corporation’s (DERM) Stock Is Down 7.39%
As of Monday, November 16, Journey Medical Corporation’s DERM share price has dipped by 7.39%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Tudor Pop
Michael Rose
Cynthia McLaughlin
| Share Statistics | DERM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $104.4 | $433.9 | 23% |
|
| Shares Out (Mil) | 28.1 | 46.5 | 36% |
|
| Institutional Ownership | 76.7% | 82.2% | 46% |
|
| Float (Mil) | 15.6 | 47.7 | 25% |
|
| Beta | na | 0.74 | na |
|
| Avg Daily Volume (000s) | 222 | 345 | 46% |
|
| Price Change (52-week) |
(51.9%) | 52.0% | 19% |
|
| Growth | DERM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.8% | 6.4% | 45% |
|
| Net Income (5yr) | (32.9%) | (1.6%) | 12% |
|
| EPS (5yr) | (24.2%) | 15.1% | 11 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.0%) | (15.1%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DERM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $70 | $289 | 23% |
|
| Net Income (TTM) (Mil) | ($5) | ($11) | 33% |
|
| EPS (TTM) | ($0.186) | ($0.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($7) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $18 | $6 | 32% |
|
| Enterprise Value (Q1) (Mil) | $127 | $331 | 24% |
|
| Valuation | DERM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.25 | 2.05 | 71% |
|
| P/E | na | 24.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | DERM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 65.9% | 69.5% | 78% |
|
| Net Margin | (7.3%) | 3.9% | 22% |
|
| ROA | (5.4%) | (23.3%) | 28% |
|
| ROE | (17.6%) | (21.8%) | 24% |
|
| Liabilities to Assets | 68.9% | 31.2% | 65% |
|
| F-Score | 4 | 3 | 33% |
|
Journey Medical Corporation did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors